Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 11/20 | 0.41 |
| ▸ | ARG2 | P78540 | 11/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30169846 | 0.78 | ARG1 (0.60) | ARG1ARG2CPB2 | |
| SCHEMBL31042229 | 0.77 | ARG1 (0.59) | ARG1ARG2CPB2 | |
| SCHEMBL31042202 | 0.77 | ARG1 (0.59) | ARG1ARG2CPB2 | |
| SCHEMBL31042199 | 0.77 | ARG1 (0.59) | ARG1ARG2CPB2 | |
| SCHEMBL31042217 | 0.77 | ARG1 (0.59) | ARG1ARG2CPB2 | |
| SCHEMBL29601687 | 0.75 | ARG2 (0.38) | ARG1ARG2NFKB1NPSR1MEN1 | |
| SCHEMBL31078534 | 0.71 | ARG1 (0.56) | ARG1ARG2CPB2BLMALDH1A1 | |
| SCHEMBL516823 | 0.70 | CPB2 (0.45) | CPB2CYP2D6NFKB1BLMNPSR1 | |
| SCHEMBL29618982 | 0.67 | — | — | |
| SCHEMBL14839486 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713446-A2 | METHANOLYTIC AGENTS AND METHODS OF USING THE SAME | Lumen Bioscience, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-20260053870-A1 | METHANOLYTIC AGENTS AND METHODS OF USING THE SAME | LUMEN BIOSCIENCE INC (US) | 2026-02-26 | — | — | US | claimed |
| EP-4713446-A2 | METHANOLYTIC AGENTS AND METHODS OF USING THE SAME | Lumen Bioscience, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260053870-A1 | METHANOLYTIC AGENTS AND METHODS OF USING THE SAME | LUMEN BIOSCIENCE INC (US) | 2026-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053870-A1 | METHANOLYTIC AGENTS AND METHODS OF USING THE SAME | MGLL, BPHL, FBL | ARG1 817/4885ARG2 1038/4885CPB2 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.